Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab vs Chemotherapy in Relapsed Small-Cell Lung Cancer
NCT02481830Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2015
- Primary completion
- Aug 2018
- Modality
- Monoclonal Antibodies
- Countries
- 25
01
Overview
Phase 3, randomised, open-label trial of nivolumab in small cell lung cancer (SCLC) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Overall Survival at 15.8 months. Started Sep 2015; status: completed.
02
Drugs
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02481830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02481830.